Ironwood posts Q2 GAAP net loss of $1.06B on acquisition costs; LINZESS sales +9%

IRONWOOD PHARMACEUTICALS INC

2023-Q2 EPS reported -$6.56 revenue$211,443,000

GAAP net loss attributable to Ironwood of $1.06B, or $6.84/share diluted, primarily from VectivBio acquisition.
Total revenues $107.4M, up 10% YoY; LINZESS U.S. net sales $270M, +9% YoY.
FDA approved LINZESS for pediatric FC ages 6-17 in June, expanding addressable market.
Acquired VectivBio for apraglutide (SBS-IF); STARS Phase III enrollment complete, data March 2024.
Raised full-year 2023 guidance: LINZESS net sales $1.055-1.075B, Ironwood revenue $435-455M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRONWOOD PHARMACEUTICALS INC reported second quarter 2023 results: revenue $107,382, net income $(1,089,478), EPS $(6.84) per share – basic. Guidance raised.

Period: second quarter 2023
Revenue: $107,382
Net income: $(1,089,478)
EPS: $(6.84) per share – basic
Guidance: raised
Result: reported results

Exact text from the filing

position, and grow Ironwood’s leadership within GI.” Second Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 2Q 2023 2Q 2022 Total revenues $ 107,382 $ 97,231 Total operating expenses 2 1,190,521 41,576 GAAP net income (loss) 2 (1,089,478 ) 37,080 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-088584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.